Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
InnoCan Pharma ( (TSE:INNO) ) has issued an announcement.
Innocan Pharma’s subsidiary, BI Sky Global, has completed the Human Repeated Insult Patch Test (HRIPT) for its cosmetic products, ensuring their safety. Additionally, the company has achieved a significant sales milestone by selling an average of 5,000 units per day in 2024, far exceeding the typical production quantities in the cosmetics industry. This accomplishment highlights Innocan’s robust market presence and the potential for further expansion, delivering considerable value to shareholders.
More about InnoCan Pharma
Innocan Pharma is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, it has developed a CBD-loaded liposome drug delivery platform for non-opioid pain management. In the wellness sector, Innocan markets a wide range of self-care and beauty products to promote a healthier lifestyle through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced online sales.
YTD Price Performance: -9.29%
Average Trading Volume: 11,500
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $33.87M
See more insights into INNO stock on TipRanks’ Stock Analysis page.